1-20 of 34
Tao Wang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract PO-036: A deep learning alternative to regional molecular testing for HPV status

Stephanie G. Craig, Richard Gault, Kristopher D. McCombe, Andrew Moyes, Youcheng Sun, Tao Wang, Andrew Schache, Terry M. Jones, Janet M. Risk, Philip Gunning, Valerie Gaborieau, Paul Brennan, Behnoush Abedi-Ardekani, Jacqueline A. James
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (18_Supplement): PO-036.
https://doi.org/10.1158/1557-3265.AACRAHNS23-PO-036
Published: 15 September 2023
View article titled, Abstract PO-036: A deep learning alternative to regional molecular testing for HPV status
Journal Articles

A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2+ Breast Cancer

Jamunarani Veeraraghavan, Carolina Gutierrez, Carmine De Angelis, Robert Davis, Tao Wang, Tomas Pascual, Pier Selenica, Katherine Sanchez, Hiroaki Nitta, Monesh Kapadia, Anne C. Pavlick, Patricia Galvan, Brent Rexer, Andres Forero-Torres, Rita Nanda, Anna M. Storniolo, Ian E. Krop, Matthew P. Goetz, Julie R. Nangia, Antonio C. Wolff, Britta Weigelt, Jorge S. Reis-Filho, Susan G. Hilsenbeck, Aleix Prat, C. Kent Osborne, Rachel Schiff, Mothaffar F. Rimawi
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3101–3109.
https://doi.org/10.1158/1078-0432.CCR-22-3753
Published: 15 August 2023
View article titled, A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
Open the PDF for A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy

Meredith L. Frank, Kaylene Lu, Can Erdogan, Yi Han, Jian Hu, Tao Wang, John V. Heymach, Jianjun Zhang, Alexandre Reuben
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 994–1008.
https://doi.org/10.1158/1078-0432.CCR-22-2469
Published: 14 March 2023
View article titled, T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy
Open the PDF for T-Cell Receptor Repertoire Sequencing in the Era of Cancer Immunotherapy in another window
Journal Articles

Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting

Thomas Pfeiffer, Ifigeneia Tzannou, Mengfen Wu, Carlos Ramos, Ghadir Sasa, Caridad Martinez, Premal Lulla, Robert A. Krance, Lauren Scherer, Daniel Ruderfer, Swati Naik, Claire Bocchini, Iain P. Fraser, Badrish Patel, Dany Ward, Tao Wang, Helen E. Heslop, Ann M. Leen, Bilal Omer
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (2): 324–330.
https://doi.org/10.1158/1078-0432.CCR-22-2415
Published: 17 January 2023
View article titled, Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting
Open the PDF for Posoleucel, an Allogeneic, Off-the-Shelf Multivirus-Specific T-Cell Therapy, for the Treatment of Refractory Viral Infections in the Post-HCT Setting in another window
Journal Articles

Correction: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling

Tao Wang, Wen Song, Yuan Chen, Ruibao Chen, Zhuo Liu, Licheng Wu, Mingchao Li, Jun Yang, Liang Wang, Jihong Liu, Zhangqun Ye, Chenguang Wang, Ke Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (13): 2970.
https://doi.org/10.1158/1078-0432.CCR-22-1796
Published: 01 July 2022
View article titled, Correction: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling
Open the PDF for Correction: Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling in another window
Journal Articles

Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma

Raquibul Hannan, Osama Mohamad, Alberto Diaz de Leon, Subrata Manna, Laurentiu M. Pop, Ze Zhang, Samantha Mannala, Alana Christie, Scott Christley, Nancy Monson, Dan Ishihara, Eric J. Hsu, Chul Ahn, Payal Kapur, Mingyi Chen, Yull Arriaga, Kevin Courtney, Brandi Cantarel, Edward K. Wakeland, Yang-Xin Fu, Ivan Pedrosa, Lindsay Cowell, Tao Wang, Vitaly Margulis, Hak Choy, Robert D. Timmerman, James Brugarolas
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (24): 6716–6725.
https://doi.org/10.1158/1078-0432.CCR-21-2083
Published: 15 December 2021
View article titled, Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma
Open the PDF for Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4939.
https://doi.org/10.1158/1078-0432.CCR-21-2431
Published: 01 September 2021
View article titled, Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Journal Articles

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

Carmine De Angelis, Xiaoyong Fu, Maria Letizia Cataldo, Agostina Nardone, Resel Pereira, Jamunarani Veeraraghavan, Sarmistha Nanda, Lanfang Qin, Vidyalakshmi Sethunath, Tao Wang, Susan G. Hilsenbeck, Matteo Benelli, Ilenia Migliaccio, Cristina Guarducci, Luca Malorni, Lacey M. Litchfield, Jiangang Liu, Joshua Donaldson, Pier Selenica, David N. Brown, Britta Weigelt, Jorge S. Reis-Filho, Ben H. Park, Sara A. Hurvitz, Dennis J. Slamon, Mothaffar F. Rimawi, Valerie M. Jansen, Rinath Jeselsohn, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4870–4882.
https://doi.org/10.1158/1078-0432.CCR-19-4191
Published: 01 September 2021
View article titled, Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer
Open the PDF for Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform

Durga Udayakumar, Ze Zhang, Yin Xi, Durgesh K. Dwivedi, Michael Fulkerson, Sydney Haldeman, Tiffani McKenzie, Qurratulain Yousuf, Allison Joyce, Asghar Hajibeigi, Hollis Notgrass, Alberto Diaz de Leon, Qing Yuan, Matthew A. Lewis, Ananth J. Madhuranthakam, Robert C. Sibley, Roy Elias, Junyu Guo, Alana Christie, Renée M. McKay, Jeffrey A. Cadeddu, Aditya Bagrodia, Vitaly Margulis, James Brugarolas, Tao Wang, Payal Kapur, Ivan Pedrosa
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (17): 4794–4806.
https://doi.org/10.1158/1078-0432.CCR-21-0706
Published: 01 September 2021
View article titled, Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform
Open the PDF for Deciphering Intratumoral Molecular Heterogeneity in Clear Cell Renal Cell Carcinoma with a Radiogenomics Platform in another window
Includes: Supplementary data
Journal Articles

Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22

Hagop M. Kantarjian, Wendy Stock, Ryan D. Cassaday, Daniel J. DeAngelo, Elias Jabbour, Susan M. O'Brien, Matthias Stelljes, Tao Wang, M. Luisa Paccagnella, Kevin Nguyen, Barbara Sleight, Erik Vandendries, Alexander Neuhof, A. Douglas Laird, Anjali S. Advani
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2021) 27 (10): 2742–2754.
https://doi.org/10.1158/1078-0432.CCR-20-2399
Published: 15 May 2021
View article titled, Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22
Open the PDF for Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22 in another window
Includes: Supplementary data
Journal Articles

Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer

Erika J. Crosby, Chaitanya R. Acharya, Anthony-Fayez Haddad, Christopher A. Rabiola, Gangjun Lei, Jun-Ping Wei, Xiao-Yi Yang, Tao Wang, Cong-Xiao Liu, Kay U. Wagner, William J. Muller, Lewis A. Chodosh, Gloria Broadwater, Terry Hyslop, Jonathan H. Shepherd, Daniel P. Hollern, Xiaping He, Charles M. Perou, Shengjie Chai, Benjamin K. Ashby, Benjamin G. Vincent, Joshua C. Snyder, Jeremy Force, Michael A. Morse, Herbert K. Lyerly, Zachary C. Hartman
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4670–4681.
https://doi.org/10.1158/1078-0432.CCR-20-0389
Published: 01 September 2020
View article titled, Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer
Open the PDF for Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer in another window
Includes: Supplementary data
Journal Articles

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon, Alana Christie, Zhiqun Xie, Layton Woolford, Nirmish Singla, Allison Joyce, Haley Hill, Ananth J. Madhuranthakam, Qing Yuan, Yin Xi, Yue Zhang, Jenny Chang, Oluwatomilade Fatunde, Yull Arriaga, Arthur E. Frankel, Sanjeeva Kalva, Song Zhang, Tiffani McKenzie, Oscar Reig Torras, Robert A. Figlin, Brian I. Rini, Renée M. McKay, Payal Kapur, Tao Wang, Ivan Pedrosa, James Brugarolas
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 793–803.
https://doi.org/10.1158/1078-0432.CCR-19-1459
Published: 14 February 2020
View article titled, HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma
Open the PDF for HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma in another window
Includes: Supplementary data
Journal Articles

TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer

Mothaffar F. Rimawi, Polly Niravath, Tao Wang, Brent N. Rexer, Andres Forero, Antonio C. Wolff, Rita Nanda, Anna M. Storniolo, Ian Krop, Matthew P. Goetz, Julie R. Nangia, Sao Jiralerspong, Anne Pavlick, Jamunarani Veeraraghavan, Carmine De Angelis, Carolina Gutierrez, Rachel Schiff, Susan G. Hilsenbeck, C. Kent Osborne
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (4): 821–827.
https://doi.org/10.1158/1078-0432.CCR-19-0851
Published: 14 February 2020
View article titled, TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer
Open the PDF for TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy

Carmine De Angelis, Chandandeep Nagi, Cliff C. Hoyt, Linying Liu, Kristin Roman, Chichung Wang, Yi Zheng, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Paolo Nuciforo, Tao Wang, Anna Tsimelzon, Sufeng Mao, Susan G. Hilsenbeck, Meghana V. Trivedi, Maria Letizia Cataldo, Anne Pavlick, Antonio C. Wolff, Britta Weigelt, Jorge S. Reis-Filho, Aleix Prat, Carolina Gutierrez, Charles Kent Osborne, Mothaffar F. Rimawi, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (3): 738–745.
https://doi.org/10.1158/1078-0432.CCR-19-1402
Published: 03 February 2020
View article titled, Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy
Open the PDF for Evaluation of the Predictive Role of Tumor Immune Infiltrate in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Anti-HER2 Therapy without Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia

Wen-Tao Wang, Cai Han, Yu-Meng Sun, Zhen-Hua Chen, Ke Fang, Wei Huang, Lin-Yu Sun, Zhan-Cheng Zeng, Xue-Qun Luo, Yue-Qin Chen
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (9): 2795–2808.
https://doi.org/10.1158/1078-0432.CCR-18-1474
Published: 01 May 2019
View article titled, Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia
Open the PDF for Activation of the Lysosome-Associated Membrane Protein LAMP5 by DOT1L Serves as a Bodyguard for MLL Fusion Oncoproteins to Evade Degradation in Leukemia in another window
Includes: Supplementary data
Journal Articles

A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent In Vitro and In Vivo Antitumor Activity in Preclinical Models of Small Cell Lung Cancer

Paul Ponath, Daniel Menezes, Chin Pan, Bing Chen, Miho Oyasu, Debbie Strachan, Heidi LeBlanc, Huadong Sun, Xi-Tao Wang, Vangipuram S. Rangan, Shrikant Deshpande, Sandra Cristea, Kwon-Sik Park, Julien Sage, Pina M. Cardarelli
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (20): 5178–5189.
https://doi.org/10.1158/1078-0432.CCR-18-0018
Published: 15 October 2018
View article titled, A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <em>In Vitro</em> and <em>In Vivo</em> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer
Open the PDF for A Novel, Fully Human Anti–fucosyl-GM1 Antibody Demonstrates Potent <em>In Vitro</em> and <em>In Vivo</em> Antitumor Activity in Preclinical Models of Small Cell Lung Cancer in another window
Includes: Supplementary data
Journal Articles

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

Xiaowei Xu, Carmine De Angelis, Kathleen A. Burke, Agostina Nardone, Huizhong Hu, Lanfang Qin, Jamunarani Veeraraghavan, Vidyalakshmi Sethunath, Laura M. Heiser, Nicholas Wang, Charlotte K.Y. Ng, Edward S. Chen, Alexander Renwick, Tao Wang, Sarmistha Nanda, Martin Shea, Tamika Mitchell, Mahitha Rajendran, Ian Waters, Daniel J. Zabransky, Kenneth L. Scott, Carolina Gutierrez, Chandandeep Nagi, Felipe C. Geyer, Gary C. Chamness, Ben H. Park, Chad A. Shaw, Susan G. Hilsenbeck, Mothaffar F. Rimawi, Joe W. Gray, Britta Weigelt, Jorge S. Reis-Filho, C. Kent Osborne, Rachel Schiff
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (17): 5123–5134.
https://doi.org/10.1158/1078-0432.CCR-16-2191
Published: 31 August 2017
View article titled, HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer
Open the PDF for HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2<sup>+</sup> Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors

Emiliano Calvo, Jean-Charles Soria, Wen Wee Ma, Tao Wang, Rastilav Bahleda, Anthony W. Tolcher, Diana Gernhardt, Joseph O'Connell, Robert Millham, Nagdeep Giri, Michael J. Wick, Alex A. Adjei, Manuel Hidalgo
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (5): 1177–1185.
https://doi.org/10.1158/1078-0432.CCR-15-2301
Published: 28 February 2017
View article titled, A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
Open the PDF for A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling

Tao Wang, Wen Song, Yuan Chen, Ruibao Chen, Zhuo Liu, Licheng Wu, Mingchao Li, Jun Yang, Liang Wang, Jihong Liu, Zhangqun Ye, Chenguang Wang, Ke Chen
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (6): 1531–1544.
https://doi.org/10.1158/1078-0432.CCR-15-1632
Published: 15 March 2016
View article titled, Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling
Open the PDF for Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling in another window
Includes: Supplementary data
Journal Articles

Abstract A25: Variations of human papillomavirus type 16 in cervical, lung, and skin cancers in Sichuan, China

Jian Zhang, Tao Wang, Min Han, Zhihui Yang, Min Zhang, Lunxu Liu, Bin Zhou, Yue Chen, Qiannan Hou, Yanyun Wang, Ting Lai, Lin Zhang, Huaizhong Hu, Mingrong Xi
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (14_Supplement): A25.
https://doi.org/10.1158/1078-0432.TCMUSA10-A25
Published: 02 February 2016
View article titled, Abstract A25: Variations of human papillomavirus type 16 in cervical, lung, and skin cancers in Sichuan, China